Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Alone or With Durvalumab Prior to Surgery in High-grade Epithelial Ovarian Cancer
NCT04644289Phase 2Recruiting
- Sponsor
- AGO Research
- Start
- May 2022
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab in epithelial ovarian cancer (EOC), sponsored by AGO Research. Started May 2022; status: recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04644289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644289.